JANX - Janux Therapeutics surges amid report of takeover interest
2024-04-10 13:48:32 ET
More on Janux Therapeutics
- Janux Therapeutics: Yes There's New Data; No It's Not A Buy Here
- Trial Data Triggers Massive Rally In Janux Therapeutics
- Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
- Cantor starts Janux at overweight, cites TCE leadership position
- Janux Therapeutics GAAP EPS of -$0.25 beats by $0.16, revenue of $2.46M beats by $1.72M